Rapamycin formulations and methods of their use
AssigneeSanten Pharmaceutical Co., Ltd.
InventorsSreenivasu MUDUMBA, Philippe JM DOR, Thierry NIVAGGIOLI, David A. WEBER, Sidiq FAROOQ
Life of this patent
Estimating the term…
Abstract
Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
Claims8
A method for treating dry age-related macular degeneration in a human subject, the method comprising administering to the human subject by intraocular or periocular injection of a liquid formulation containing an amount of rapamycin effective to treat dry-age macular degeneration in the human subject, wherein the liquid formulation is a liquid solution that forms a non-dispersed mass when injected into the vitreous, and the liquid formulation comprises about 2% (w/w) rapamycin, about 94% (w/w) PEG 400, and about 4% (w/w) ethanol.
Dependencies are inferred from the claim text.